Fig. 4.

Clinical disease in DON-treated, SINV-infected mice. (a) Kaplan-Meyer plot of time to development of signs of neurologic disease. All untreated SINV-infected mice developed clinical signs by 7 DPI, while over half of the low and high dose DON-treated, SINV-infected mice remained clinically normal (****p ≤ 0.0001 by log-rank [Mantel Cox] test; N=9–32 mice over 3 separate independent experiments). (b) Changes in body weight. SINV-infected mice receiving low-dose (0.3 mg/kg) DON treatment lost less weight by 7 DPI compared to untreated SINV-infected mice, but not as much as mice receiving high-dose (0.6 mg/kg) DON treatment (****p ≤ 0.0001, one-way ANOVA with p ≤ 0.01 by Bonferroni’s multiple comparison tests; N=9–32 mice over three separate independent experiments; data presented as mean ± SEM)